Abstract:Abstract Abstract Background: Chemokine (C-C Motif) Ligand 17 is a protein coding gene. This chemokine plays important roles in T cell development in thymus as well as in trafficking and activation of mature T cells. Diseases associated with CCL17 include mycosis fungoides, paragonimiasis and some hematologic malignancies such as Hodgkin¡¯s lymphoma, B cell lymphoma, and Nasal natural killer/T cell lymphoma (NNKTL). However, our knowledge of the expression levels of CCL17 in B-cell acute lymphoblastic leukemia (ALL) remains limited. Aims: The purpose of this study was to investigate the expression levels of human CCL17 messenger RNA in adult B-cell ALL. Methods: A real-time quantitative reverse transcription-polymerase chain reaction assay based on TaqMan fluorescence methodology was used to quantify the CCL17 mRNA copy number in the bone marrow cells from patients with adult leukemia and in 16 human hematologic malignant cell lines. Normal marrow samples from the allogeneic stem cell transplantation donors were served as control. Informed consent was obtained for every marrow sample. Results: Expression levels of the CCL17 gene in leukemic cell lines, leukemia patients and normal donor marrow are shown in Figure 1. These results showed that the relative levels of CCL17 gene expression in marrow from 189 newly diagnosed B-cell ALL(median 0.23%; range 0%¡«69000%) was significantly higher than those of bone marrow from the 43 healthy donors (median 0.05%; range 0%¡«6.87%;P =0.0007). Significant CCL17 mRNA overexpression was found in the de novo B-cell ALL patients compared with 102 treated B-cell ALL patients(median 0.02%; range 0%¡«3339%) who achieved complete remission or 70 de novo AML (median 0.02%; range 0%¡«9.132%;P¡¯s <0.0001). The expression levels of CCL17 was higher in 21 refractory/relapsed B-cell ALL patients (median 0.68%; range 0.003%¡«13490%) than that newly diagnosed B-cell ALL, but no statistical significant difference was observed (P=0.34). Besides, no statistical significant difference was observed in 16 newly diagnosed T-cell ALL(median 0.06%, range 0%¡«9.947%), 70 AML and 43 healthy donors (P¡¯s > 0.05), but it was higher in SupB15 and Nalm-6 cells from B-cell ALL cell lines than in other cells from AML or T-cell ALL cell lines. Conclusion: These results suggest that abnormal expression of CCL17 in leukemia may be involved in the pathomechanism of B-cell ALL. Figure 1 A: CCL17 expression levels in B-cell ALL and healthy donors( ** represent P< 0.01). B: CCL17 expression levels in human hematologic malignant cell lines. Figure 1. A: CCL17 expression levels in B-cell ALL and healthy donors( ** represent P< 0.01). / B: CCL17 expression levels in human hematologic malignant cell lines. Disclosures No relevant conflicts of interest to declare.

[Expression of SCL Gene in Bone Marrow Stromal Cells from Patients with Leukemia].

Expression of BCL2L12 gene in de novo acute myeloid leukemia and its clinical implications]

SCL expression at critical points in human hematopoietic lineage commitment

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

Expression and Functions of the STAT3-SCLIP Pathway in Chronic Myeloid Leukemia Cells.

[Expression Level of SET Gene in Acute Myeloid Leukemia and Its Clinical Significance].

Expression of Neuropilin-1 Gene in Bone Marrow Stromal Cells from Patients with Myeloid Leukemia and Normal Individuals

[Expressions of Transcription Factor GATA-1 and GATA-2 Genes in Bone Marrow Stromal Cells from Patients with Leukemia].

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

[Expression of Genes Psma6 and Slc25a4 in Patients with Acute Monocytic Leukemia].

Gene Expression in CD34(+) Cells from Normal Bone Marrow and Leukemic Origins.

The Expression of Neuropilin-1 Gene in Bone Marrow Stromal Cells from Patients with CML and Normal Individuals

Kdr and Sema3 Genes Expression in Bone Marrow Stromal Cells and Hematopoietic Cells from Leukemia Patients and Normal Individuals

Bone marrow mesenchymal stromal cells from acute myelogenous leukemiapatients exhibit aberrant gene expression profiles and secreted protein levels

The differential expression pattern of the BMI-1, SALL4 and ABCA3 genes in myeloid leukemia

Are Leukemic Patient Bone Marrow Mesenchymal Stem Cells Malignant?

Stromal-derived Factor-1 Deficiency in the Bone Marrow of Acute Myeloid Leukemia

Lower BCL11B Expression is Associated with Adverse Clinical Outcome for Patients with Myelodysplastic Syndrome

Abnormal Expression of the Chemokine (C-C Motif) Ligand 17 Gene in Adult B-Cell Acute Lymphoblastic Leukemia

Expression of SALL4 in Acute Myeloid Leukemia and Its Potential Clinical Significance

CCL23 Expression in Adult Patients with Acute Myeloid Leukemia